Tag Archives: Pandemic

Nagorno-Karabakh ceasefire hopes sink as death toll rises

By Nailia Bagirova and Nvard Hovhannisyan

BAKU/YEREVAN (Reuters) – Hopes of a humanitarian ceasefire ending fighting over Nagorno-Karabakh sank further on Thursday as the death toll mounted and Armenia and Azerbaijan accused each other of launching new attacks.

Armenia accused Turkey of blocking flights carrying emergency aid from using its airspace, and Azerbaijan’s president warned of “new victims and new bloodshed” from fighting over the mountain enclave that broke out on Sept. 27.

Azeri President Ilham Aliyev demanded that Armenia “halt attempts to capture liberated territories back” and said his country would take all regions of Nagorno-Karabakh if Armenia “acts negatively.”

Last Saturday’s ceasefire, aimed at letting the sides swap detainees and bodies of those killed in the clashes, has had little impact on the fighting around Nagorno-Karabakh, a mountain territory internationally recognized as part of Azerbaijan but populated and governed by ethnic Armenians.

In the deadliest flare-up since a 1990s war killed about 30,000 people, 604 Nagorno-Karabakh defense personnel have been killed, ethnic Armenian authorities say.

On Thursday, three Azeri civilians were killed and three were wounded during a funeral in Azerbaijan’s Terter region when an artillery shell fell on a cemetery, presidential aid Hikmet Hajiyev said on Twitter.

That would add to Azeri estimates provided on Wednesday that 43 civilians had so far been killed. Baku does not disclose military casualties. The prosecutor’s office said earlier on Thursday that two civilians had been wounded in shelling of the Aghdam area.

The Armenian prosecutor-general’s office said Azeri drones had killed two soldiers in the Vardenis region of Armenia on Wednesday, raising the Armenian military death toll to five. The servicemen were not involved in military action, it said.

A tweet from Nagorno-Karabakh’s ombudsman accused Azerbaijan of using heavy rockets to target civilian infrastructure in the town of Stepanakert.

Reuters could not independently verify the reports.

HUMANITARIAN CONCERNS

International organizations, including the International Committee of the Red Cross, have warned that the conflict, coming on top of the COVID-19 pandemic, could leave tens of thousands of people in need of aid over coming months.

Zareh Sinanyan, Armenian High Commissioner for Diaspora Affairs, said the delivery of 100 tonnes of aid from the United States was being delayed as Turkey had prohibited Armenia-bound humanitarian aid flights over its airspace.

Armenia’s civil aviation committee was told on Wednesday the Qatar Airways flight from Los Angeles was cancelled but gave no reasons, said the committee’s head, Tatevik Revazyan.

“We have grounds to claim that Turkey closed the air route deliberately,” Revazyan told Reuters, adding alternative routes over Russia or Georgia were being sought.

Turkey’s foreign ministry, which handles airspace issues, was not immediately available to comment.

Aside from humanitarian concerns, fears are growing of Russia and Turkey being sucked in. Turkey’s military exports to its ally Azerbaijan have risen six-fold this year, data shows, and Armenia has a defense pact with Russia.

In a phone call on Wednesday with Turkish President Tayyip Erdogan, Russian leader Vladimir Putin expressed concerns about the participation of Middle East fighters in the conflict, though Turkey and Azerbaijan deny the presence of such fighters.

The fighting is also close to Azeri pipelines which carry natural gas and oil to international markets. Aliyev accused Armenia on Wednesday of trying to attack the pipelines, a charge that Armenia denied.

(Additional reporting by Margarita Antidze in Tbilisi and Jonathan Spicer in Ankara; Writing by Sujata Rao; Editing by Timothy Heritage)

World stocks whipsaw on pandemic worries, gold gains

By Koh Gui Qing and Carolyn Cohn

NEW YORK/LONDON (Reuters) – U.S. and European shares whipsawed between modest gains and losses on Wednesday as investors tried to brush aside market risks to focus on the positive, but caution prevailed in the gold market with prices jumping more than 1%.

Reports that some European countries have started to close schools and cancel surgeries due to a resurgence in the COVID-19 pandemic weighed on sentiment, though European shares still managed to trim earlier losses.

In the United States, investors looked to positive earnings reports by investment bank Goldman Sachs Group and UnitedHealth Group Inc, the largest U.S. health insurer, and tried to shelve concerns over two stalled trials for COVID-19 treatment and vaccine that rattled markets on Tuesday.

Investors are hoping that a quick development of a treatment or vaccine for COVID-19 would end the pandemic and aid a recovery in the world economy.

“Bulls are looking to get back on track this morning,” Paul Hickey, a co-founder of Bespoke Investment Group LLC, wrote in a note, but added that an upbeat mood may not hold.

Major U.S. stock indices had given up early gains by 1426 GMT. The S&P 500 was largely flat at 3,512.90, and the Dow Jones Industrial Average was also little changed at 28,655.36. The Nasdaq Composite fell 30 points, or 0.3%, to 11,832.32.

The pan-European STOXX 600 narrowed losses and was down 0.1%, while markets in Frankfurt and Paris were up 0.1% and flat respectively. London, buffeted in part by Brexit angst, dropped 0.6%. World stocks were little changed but still within sight of an all-time high struck on Sept. 3.

Moving beyond bar and pub closures, the Czech Republic shifted schools to distance learning and hospitals started cutting non-urgent medical procedures to free beds.

Moscow authorities said on Wednesday they would introduce online learning for many students starting on Monday, while Northern Ireland announced schools would close for two weeks.

Asian stocks also had a lackluster showing. MSCI’s broadest index of Asia-Pacific shares outside of Japan had tracked Wall Street’s losses overnight to end a seven-day rally.

The index was last down 0.11%, having toppled from a two-and-a-half-year high of 588.76 touched on Tuesday. Chinese shares closed down 0.7%.

Bolstered by uncertainty around the pandemic, the price of gold, a safe-haven asset, climbed by more than 1% to a high of $1,912.51 an ounce.

Government bonds also benefited from investor caution. German bund yields, which move inversely to prices, hit their lowest since May, while the 10-year U.S. Treasury yield dipped to 0.7173%.

The U.S. dollar softened after pulling its best day in three weeks on Tuesday. Its index against a basket of six major currencies fell 0.3% to 93.25. That helped the euro to firm slightly to $1.1768.

Concerns that fuel demand will continue to falter as rising coronavirus cases across Europe and in the United States, the world’s biggest oil consumer, dragged on oil prices. Brent and U.S. crude pared earlier gains and were at $43.19 and $40.99 a barrel, respectively.

(Reporting by Koh Gui Qing; Editing by Lisa Shumaker)

Humanitarian crisis feared as Nagorno-Karabakh ceasefire buckles

By Nvard Hovhannisyan and Nailia Bagirova

YEREVAN/BAKU (Reuters) – Armenia and Azerbaijan accused each other on Tuesday of violating a ceasefire agreed three days ago to quell fighting over Nagorno-Karabakh, drawing warnings from international groups of a humanitarian crisis in the region.

The Russia-brokered truce is buckling despite mounting calls from world powers to halt the fighting, with U.S. Secretary of State Mike Pompeo and the Minsk Group security watchdog among those urging greater commitment to the ceasefire terms.

A Reuters cameraman witnessed shelling in the town of Martuni in Nagorno-Karabakh, a mountain enclave which is internationally recognized as part of Azerbaijan but governed and populated by ethnic Armenians.

A Reuters television crew in Terter in Azerbaijan also said the city center was being shelled earlier on Tuesday.

Azerbaijan accused Armenian forces of “grossly violating the humanitarian truce”, which was agreed on Saturday to allow the sides to swap prisoners and bodies of those killed..

Defense ministry spokesman Vagif Dargiahly said Armenia was shelling the Azeri territories of Goranboy and Aghdam, as well as Terter. Azeri forces were not violating the truce, he added.

Armenian defense ministry spokeswoman Shushan Stepanyan denied the accusation. She said Azeri forces had resumed military operations after an overnight lull, “supported by active artillery fire in the southern, northern, northeastern and eastern directions”.

The fighting which erupted on Sept. 27, is the worst since a 1991-94 war over Nagorno-Karabakh that killed about 30,000.

It is being closely watched abroad, not only due to its proximity to Azeri energy pipelines to Europe but also because of fears that Russia and Turkey could be drawn in.

Russia has a defense pact with Armenia and Turkey is allied with Azerbaijan.

“CATASTROPHIC CONSEQUENCES”

The Minsk Group called on the Armenian and Azeri leaders to immediately implement the ceasefire to prevent “catastrophic consequences for the region”.

The 11-member group includes both Russia and Turkey, but the latter is not involved in the Nagorno-Karabakh talks. Turkish Foreign Minister Mevlut Cavusoglu suggested holding talks that would include Turkey.

Ceasefire demands were “reasonable,” according to Cavusoglu, but he said the international community should ask Armenia to withdraw from Azeri territory.

“Sadly no such call is being made,” he told reporters.

Influential Turkish politician Devlet Bahceli, whose party supports President Erdogan’s AKP in parliament, took a more belligerent note, telling Azerbaijan to secure Nagorno-Karabakh by “hitting Armenia over the head over and over again.”

While Turkey denies military involvement in Nagorno-Karabakh, Armenian President Armen Sarkissian told Germany’s Bild newspaper Ankara’s behavior was worrying.

“I worry because, firstly, there is a third party involved. If it were only about Nagorno-Karabakh and Azerbaijan, I would be much more hopeful that the conflict can be contained,” he said.

DEAD AND WOUNDED

The death toll has risen further, meanwhile. Nagorno-Karabakh officials said 542 servicemen had been killed so far, up 17 from Monday.

Azerbaijan has reported 42 Azeri civilian deaths and 206 wounded since Sept. 27. It has not disclosed military casualties.

Martin Schuepp, Eurasia regional director for the International Committee of the Red Cross (ICRC), said his organization was in “continuous discussions” to facilitate the handover of detainees or bodies of those killed.

But the security situation meant “it has not been possible for us to access all locations that might have been affected,” Schuepp said.

The conflict is also worsening the spread of COVID-19, World Health Organization spokesman Tarik Jasarevic told a United Nations briefing in Geneva.

Armenia’s new cases had doubled over the past 14 days as of Monday, while new infections were up approximately 80% over the past week in Azerbaijan, Jasarevic said. He warned of “direct disruption to health care and a further burden on health systems that are already stretched during the COVID pandemic.”

With tens of thousands of people potentially needing help in coming months, the ICRC is appealing for another 9.2 million Swiss francs ($10.10 million) to fund its humanitarian efforts in the region, Schuepp said.

(Additional reporting by Margarita Antidze in Tbilisi, Riham Alkousaa in Berlin, Stephanie Ulmer-Nebehay in Geneva, Tuvan Gumrukcu and Jonathan Spicer in Ankara; Writing by Sujata Rao; Editing by Giles Elgood, Timothy Heritage, William Maclean)

How poor regions lose out because of U.S. census undercounts

By Nick Brown

ESPANOLA, New Mexico (Reuters) – Getting an accurate count of America’s population has proven difficult in the 2020 Census as the coronavirus pandemic has hampered voluntary responses and forced officials to scale back door-knocking efforts.

The administration of President Donald Trump has placed other hurdles on the path to an accurate count. Its attempt to add a question about citizenship to the census earlier this year likely discouraged undocumented immigrants from filling out the survey, even though the administration’s effort failed, demographics experts say. Local officials nationwide worry about the impact of undercounts on their communities.

“This is going to be the worst response rate we’ve ever had,” said Lauren Reichelt, Health and Human Services Director for Rio Arriba County, New Mexico.

Rio Arriba is typical of other regions across the United States that are hardest to count – and have the most to lose from an undercount. It’s poor, rural and home to many undocumented immigrants. Low population tallies can rob such areas of badly needed federal dollars for affordable housing and child care, for instance, or resources to fight America’s opioid epidemic, according to local officials in some of the most undercounted regions in the last census, taken in 2010.

“Persistent undercounting in communities that would benefit most from targeted public and private investment makes it harder to address the very barriers that contribute to a less accurate census,” said Terri Ann Lowenthal, a consultant on census and statistical issues and former congressional staffer overseeing census matters.

The Census Bureau and the White House declined to comment for this story.

The Bureau is nearing the end of the 2020 edition of the decennial count, which will guide the allocation of $1.5 trillion a year in federal aid. The census is also a linchpin of American democracy because the population counts are used to determine the number of Congressional representatives assigned to a state and to draw maps of electoral districts.

Some of the hardest-to-count regions in the last census might be even harder to survey this year as the country reels from the coronavirus pandemic, according to a Reuters analysis of Census data. They include border areas in Texas, the lowlands of Mississippi and the northern plains of New Mexico.

‘I ALWAYS RELAPSE’

Rio Arriba officials estimated they were undercounted by 4% in 2010, after only 42% of households mailed back their census forms voluntarily. That compared to 66.5% of households that responded by mail nationally, according to Census data.

The bureau sent door-knockers to get more responses, but still had to use a Census process called imputation to estimate residency for 9.6% of Rio Arriba’s count, a far larger proportion than the national average.

Officials in the county say an accurate count would have helped narrow funding gaps that leave it without enough medicine, detox clinics, housing and other support to fight one of the community’s biggest problems: an opioid epidemic that kills people at a rate more than four times the U.S. average, according to government data.

The current U.S. Census shows no signs of reversing the trend. Rio Arriba’s voluntary response rate is running at 32%, 10 points below its 2010 rate and less than half the overall U.S. rate of 67%.

It is impossible to know exactly how much funding is lost due to an undercount, says George Washington University professor Andrew Reamer, the nation’s foremost expert on the relationship between the census and federal spending. That would require knowing exactly how many people were missed and which government programs would have served them.

Officials in Rio Arriba agree they were entitled to more federal funds for programs to address a local opioid crisis.

“A lot of the funding for my department is federal, so we end up being entitled to a lot less than we should when there’s an undercount,” said Reichelt.

The $3.4 million her department received in 2020 to fight addiction is spread thin, and even a relatively modest increase could make a big difference. The county can’t afford to build a detox center, and patients wait for weeks to get suboxone, a drug that reduces withdrawal symptoms, Reichelt said.

The Rio Arriba County Housing Authority, meanwhile, manages 54 public housing units, and assists another 25 families with rent vouchers. But the wait lists can be as long as five years, according to Reichelt.

Joey Garcia, a 32-year-old heroin addict who has been in and out of jail on drug charges, said he has struggled to get straight while on waiting lists for both subsidized housing and suboxone treatment.

“Somehow,” Garcia said, “I always relapse.”

NERVOUS TO ANSWER

The Rio Grande Valley in south Texas is a political netherworld. North of the border but south of immigration checkpoints, its four counties – Hidalgo, Cameron, Starr and Willacy – include informal communities known as colonias, often heavily populated with undocumented immigrants.

In Hidalgo, officials estimate they were undercounted by at least 10% in 2010, after just 56% of the population responded voluntarily. The Census Bureau estimated a more modest 5.4% undercount.

Either way, the undercounts reduced funding to the area’s Head Start and Low Income Heating and Energy Assistance (LIHEAP) programs, which cover only a fraction of eligible residents.

In Pueblo de Palmas, a colonia in Hidalgo County, Cristina, 35, qualifies for government-funded Head Start childcare for her four children, but only one was admitted. She asked that only her first name be used because she is an undocumented immigrant.

Both LIHEAP and Head Start are underfunded in the county. The former has a budget of $6 million, enough to serve 3-4% of qualifying households, says Jaime Longoria, the region’s community services director.

Head Start, which relies on population data to decide where to expand programs, can serve 3,700 kids in Hidalgo out of 22,000 who qualify, said Teresa Flores, the local Head Start director. An accurate count would help cover some of that gap, she said.

Cristina and her neighbor, Maria – also undocumented – both said they couldn’t remember filling out a census form in 2010 and that they were afraid to do so this year.

“I’m nervous someone will come to my house and take me away,” Maria said.

‘WE’RE BROKE’

In central Mississippi, voluntary participation in the 2010 census ranged between 45% and 60%. The rate in these areas so far this year is similar, according to Census data.

Lower funding from census undercounts has affected a crucial childcare program for low-income mothers in the nation’s poorest state, program officials said.

More than 112,000 Mississippi families are poor enough to qualify, but the program only has enough money to grant 20,000 to 25,000 vouchers, said Carol Burnett, who runs the nonprofit Mississippi Low Income Childcare Initiative.

Mississippi’s allotment under the Child Care and Development Block Grant that funds the program was $91.8 million in fiscal year 2019. An extra 1% of that total statewide – about $918,000 – could potentially serve hundreds more parents across the state, Burnett said, as the vouchers cover around $5,700 a year in expenses.

Tanisha Womack, 35, runs three daycare centers in Simpson and Smith counties, two of several counties in Mississippi that were among the hardest to count nationwide in 2010, according to the Reuters data.

Womack is certified to care for 152 children, but has just 72 children enrolled, she said, because many qualifying parents have been denied vouchers.

“We’re broke,” Womack said.

(Reporting by Nick Brown; Additional reporting by Grant Smith; Editing by Richard Valdmanis and Brian Thevenot)

More synchronized action needed to tackle COVID economic crisis, IMF’s Georgieva says

By Andrea Shalal and Marc Jones

WASHINGTON/LONDON (Reuters) – The international community must do more to tackle the economic fallout of the COVID-19 crisis, the head of the International Monetary Fund said on Monday, publicly calling on the World Bank to accelerate its lending to hard-hit African countries.

Some of the key events of the virtual and elongated annual meetings of the IMF and World Bank take place this week, with the most pressing issue how to support struggling countries.

“We are going to continue to push to do even more,” IMF Managing Director Kristalina Georgieva said during an online FT Africa summit.

“I would beg for also more grants for African countries. The World Bank has grant-giving capacity. Perhaps you can do even more… and bilateral donors can do more in that regard,” Georgieva said in an unusual public display of discord between the two major international financial institutions.

No immediate comment was available from the Bank.

Georgieva last week said the IMF had provided $26 billion in fast-track support to African states since the start of the crisis, but a dearth of private lending meant the region faced a financing gap of $345 billion through 2023.

The pandemic, a collapse in commodity prices and a plague of locusts have hit Africa particularly hard, putting 43 million more people at risk of extreme poverty, according to World Bank estimates. African states have reported more than 1 million coronavirus cases and some 23,000 deaths.

G20 governments are expected to extend for six months their Debt Service Suspension Initiative (DSSI) which has so far frozen around $5 billion of poorer countries’ debt payments, but pressure is on the main development banks and private creditors to provide relief too.

HOLDING ONTO GOLD RESERVES

Georgieva said the Fund was also pushing richer member countries to loan more of their existing Special Drawing Rights (SDR), the IMF’s currency, to countries that needed support most, and was “very committed” to finding a way forward for countries like Zambia now needing to restructure their debts.

The United States has blocked Georgieva’s early call for issuance of more SDRs, arguing that it would benefit mostly richer nations, not the developing countries that need it most.

Pledges to the Fund’s Poverty Reduction and Growth Trust, which supports low-income countries, have totaled $21 billion to date, including $14 billion in existing SDR holdings, but more resources were urgently needed, an IMF spokeswoman said.

The IMF chief dodged calls by civil society groups for the IMF to sell off some of its extensive gold reserves, saying the Fund viewed them as an important “financial buffer.”

Profit from selling less than 7% of the IMF’s gold could fund cancellation of all debt payments by the poorest countries to the IMF and World Bank for the next 15 months, the UK-based Jubilee Debt Campaign said in a new report issued Monday.

The IMF said its gold reserve of about 90.5 million ounces (2,814.1 metric tons) was worth about $137.8 billion at the end of December, compared to its historical cost of $4.4 billion.

Georgieva said countries in serious trouble must restructure their debts as soon as possible.

“This is the message for all countries in debt distress… If debt is not sustainable, please move towards restructuring, the sooner the better,” she said.

Georgieva said transparency in lending was critical for all parties, and welcomed what she called “encouraging” statements by China to move toward a more consolidated view of the debts held by the Chinese government and other institutions.

“I believe that now is the moment in this crisis, to make … transparency paramount and mandated to the extent possible everywhere,” she said.

(Reporting by Marc Jones in London, and Andrea Shalal and David Lawder in Washington; Editing by Tom Arnold, Ed Osmond and Andrea Ricci)

New U.S. COVID-19 cases rise 11% last week, Midwest hard hit

(Reuters) – The number of new COVID-19 cases rose 11% in the United States last week compared to the previous seven days, with infections spreading rapidly in the Midwest, which reported some of the highest positive test rates, according to a Reuters analysis.

Deaths fell 3% to about 4,800 people for the week ended Oct. 11, according to the analysis of state and county reports. Since the pandemic started, nearly 215,000 people have died in the United States and over 7.7 million have become infected with the novel coronavirus.

Twenty-nine out of 50 states have seen cases rise for at least two weeks in a row, up from 21 states in the prior week. They include the entire Midwest except Illinois and Missouri, as well as new hot spots in the Northeast, South and West.

In Idaho, 23.5% of more than 17,000 tests came back positive for COVID-19 last week, the highest positive test rate in the country, according to data from The COVID Tracking Project, a volunteer-run effort to track the outbreak. South Dakota, Iowa and Wisconsin also reported positive test rates above 20% last week.

For a third week in a row, testing set a record high in the country, with on average 976,000 tests conducted each day last week. The percentage of tests that came back positive for the virus rose to 5.0% from 4.6% the prior week.

The World Health Organization considers rates above 5% concerning because it suggests there are more cases in the community that have not yet been uncovered.

(Writing by Lisa Shumaker; Graphic by Chris Canipe; Editing by Tiffany Wu)

COVID-19 antibodies last at least three months; so do symptoms for many

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

COVID-19 antibodies last at least three months

People infected with COVID-19 develop antibodies targeting the new coronavirus that last for at least three months, according to two reports published on Thursday in Science Immunology. The two studies, together involving nearly 750 patients, both point to immunoglobulin G (IgG) antibodies, which start showing up well after an infection begins, as the longest-lasting. Researchers found IgG antibodies with two targets – a spike protein on the virus that helps it infect cells, and a part of the spike called the receptor binding domain (RBD) – lasted more than 100 days. While the protective effect of COVID-19 antibodies is not completely clear, Jen Gommerman of the University of Toronto, coauthor of the study, said her team also found levels of so-called neutralizing antibodies, which inactivate the virus, “appeared to be very stable.” The other study, from Harvard Medical School, reported similar findings. This means that a properly designed vaccine “should elicit a durable antibody response that has the potential to neutralize the virus,” Gommerman said. Her group also found that antibodies in saliva correlated with antibodies in blood, but at this point the saliva tests are not sensitive enough to replace blood tests.

COVID-19 symptoms linger for months for many

Three months after becoming ill, many COVID-19 patients still have symptoms, two studies confirm, and the more severe the initial infections, the higher the odds of persistent problems. In Spain, doctors checked back with 108 patients, including 44 who had been severely ill. At 12 weeks after diagnosis, 76% still reported after-effects, with 40% reporting three or more coronavirus-related health issues, doctors said in a paper posted on Thursday on medRxiv ahead of peer review. The most common complaints were shortness of breath, physical weakness, cough, chest pain, palpitations, and psychological and cognitive disorders. In a similar study of 233 U.S. COVID-19 patients – eight of whom had been severely ill – one in four still had symptoms 90 days after first feeling ill. Rates were higher for patients who had been sicker: 59.4% at 30 days and 40.6% at 90 days. “But even for very mild and initially asymptomatic cases, 14.3% have complications persist for 30 days or longer,” the authors reported on Sunday on medRxiv. In the U.S. study, the most common persistent symptoms were impaired smell and taste, difficulty concentrating, shortness of breath, memory loss, confusion, headache, heart palpitations, chest pain, pain with deep breaths, dizziness, and rapid heartbeat.

Remdesivir cut COVID-19 recovery time by 5 days

Final data from a large study of Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days among hospitalized patients, one day faster than preliminary data had indicated, researchers reported on Thursday in The New England Journal of Medicine. The 1,062-patient study compared up to up to 10 days of therapy with remdesivir – now sold in some markets as Veklury – to a placebo. The average recovery time was 10 days among those who got the Gilead drug versus 15 days in the placebo group. Among patients requiring oxygen at the start, those taking remdesivir continued to need oxygen for an average of 13 days, compared to 21 days for patients who got a placebo. In a separate analysis looking just at patients who received oxygen, the drug appeared to reduce the risk of death over the next month by 70%. “We now have data suggesting that giving remdesivir to patients on oxygen may significantly reduce their chances of death compared to other subgroups,” Dr. Andre Kalil, an infectious disease expert at the University of Nebraska Medical Center and the study’s lead investigator, said in a news release.

Coronavirus rarely travels from mother to newborn

Transmission of the new coronavirus from mothers to newborns is rare, doctors from New York-Presbyterian/Columbia University Irving Medical Center reported on Monday in JAMA Pediatrics. They studied 101 babies born to 100 mothers with COVID-19, including 10 whose mothers had been severely ill. Almost all of the babies tested negative for the virus, while tests in two newborns had indeterminate results. If these two indeterminate results are considered positive, the overall incidence of transmission was 2.0%. Even with a 2% transmission rate, “none of our babies exhibited clinical symptoms of COVID-19, either during their newborn nursery stay or during … the first few weeks of life,” coauthor Dr. Dani Dumitriu told Reuters Health by email. Roughly 90% of the newborns were breastfed at least partially. “As the country heads into what looks like a second wave of the COVID-19 pandemic, it is important to know that separation of affected mothers from their newborns may not be warranted, and direct breastfeeding appears to be safe,” study coauthor Dr. Melissa Stockwell said.

(Reporting by Nancy Lapid, Julie Steenhuysen and Will Boggs; Editing by Bill Berkrot)

Harris, fellow Democrats target Trump Supreme Court nominee on Obamacare

By Lawrence Hurley and Patricia Zengerle

WASHINGTON (Reuters) – Democratic senators including vice presidential nominee Kamala Harris on Monday painted President Donald Trump’s Supreme Court nominee Amy Coney Barrett as a threat to the Obamacare healthcare law during a deadly pandemic and denounced the Republican drive to approve her before the Nov. 3 U.S. election.

As the Senate Judiciary Committee began its four-day confirmation hearing for Barrett, Democrats voiced their strong opposition to the nomination even though they have little hope of derailing her nomination in the Republican-led Senate.

Barrett, a conservative appellate court judge nominated to replace the late liberal Justice Ruth Bader Ginsburg, sat at a table facing the senators wearing a black face mask amid the pandemic as senators made opening statements. Barrett removed the mask when she was sworn in and delivered her own opening statement.

“I believe Americans of all backgrounds deserve an independent Supreme Court that interprets our Constitution and laws as they are written,” Barrett said, reading from prepared remarks that had been made public on Sunday, with her husband and seven children sitting behind her.

Barrett’s confirmation would give the court a 6-3 conservative majority that could lead to rulings rolling back abortion rights, expanding religious and gun rights, and upholding voting restrictions, among other issues.

But it was the fate of the 2010 Affordable Care Act (ACA), Democratic former President Barack Obama’s signature domestic policy achievement that has enabled millions of Americans to obtain medical coverage, that was the focus of Harris and her fellow Democrats. Barrett has criticized a 2012 Supreme Court ruling authored by conservative Chief Justice John Roberts that upheld Obamacare.

Harris, the running mate of Trump’s Democratic election opponent Joe Biden, called the confirmation process so near the election “illegitimate.”

“I do believe this hearing is a clear attempt to jam through a Supreme Court nominee who will take away healthcare from millions of people during a deadly pandemic that has already killed more than 214,000 Americans,” Harris said, speaking via a video link.

“A clear majority of Americans want whomever wins the election to fill this seat and my Republican colleagues know that. Yet they are deliberately defying the will of the people in their attempt to roll back the rights and protections provided under the Affordable Care Act,” Harris said.

Barrett could be on the Supreme Court in time to participate in a case due to be argued on Nov. 10 in which Trump and Republican-led states are seeking to invalidate Obamacare.

Barrett will face marathon questioning from senators on Tuesday and Wednesday. The hearing is a key step before a full Senate vote by the end of October on her confirmation to a lifetime job on the court. Republicans have a 53-47 Senate majority so Barrett’s confirmation seems almost certain.

A pivotal Obamacare provision that would be thrown out if the court strikes the law down bars insurance companies from denying coverage to people with pre-existing medical conditions. In the hearing room, Democrats displayed posters of patients who could lose their medical coverage if Obamacare is invalidated, with senators recounting their individual stories.

Repeated Republican efforts to repeal Obamacare in Congress have fallen short, and Republicans have taken the effort to the courts.

Republican Senator Ted Cruz said the Democratic focus on healthcare and other policy issues showed they were not contesting Barrett’s qualifications to serve as a justice.

Republican Senator Lindsey Graham, who chairs the committee, opened the hearing by saying it would be “a long contentious week” but implored senators to make the proceedings respectful.

“Let’s remember, the world is watching,” Graham added.

“This is probably not about persuading each other, unless something really dramatic happens. All Republicans will vote yes and all Democrats will vote no,” Graham said.

‘MAD RUSH’

Democratic Senator Patrick Leahy condemned the Republican “mad rush” to fill the vacancy.

“They see the ability to take the courts from being independent to making them instead an arm of the far right and the Republican Party, with the potential to accomplish in courts what they have failed to accomplish by votes in the halls of Congress. And at the top of the hit list is the Affordable Care Act,” Leahy said.

Graham defended the Republican approach even while acknowledging that four years earlier they had refused to act on Obama’s nominee to fill a Supreme Court vacancy because it was an election year, and that no Supreme Court nominee had a confirmation process so close to an election.

The Senate’s Republican leaders rejected Democratic pleas to delay the hearing over COVID-19 concerns.

Due to the pandemic, Harris and some other senators participated remotely. Republican Senator Mike Lee attended in person nine days after revealing he head tested positive for the coronavirus, arriving wearing a light-blue surgical mask. He took off the mask while giving his opening statement.

Barrett is a devout Catholic who has expressed opposition to abortion. Christian conservative activists long have hoped for the court to overturn the landmark 1973 Roe v. Wade ruling that legalized abortion nationwide.

Democratic Senator Cory Booker said that “Senate Republicans have found a nominee in Judge Barrett who they know will do what they couldn’t do – subvert the will of the American people and overturn Roe v. Wade.”

Republicans sought to portray the Democrats as attacking Barrett on religious grounds, though the Democrats steered clear of doing so. Speaking to reporters in Delaware, Biden said Barrett’s Catholic faith should not be considered during the confirmation process. Biden was the first Catholic U.S. vice president.

“This nominee said she wants to get rid of the Affordable Care Act. The president wants to get rid of the Affordable Care Act,” Biden said. “Let’s keep our eye on the ball.”

(Reporting by Lawrence Hurley, Andrew Chung and Patricia Zengerle; Editing by Will Dunham)

As globe gallops into vaccine trials, insurers remain unfazed

By Noor Zainab Hussain, Carolyn Cohn and Ludwig Burger

LONDON/FRANKFURT (Reuters) – The world is racing towards a vaccine in record time, stirring public concerns about safety to the extent that nine leading developers have felt compelled to issue a pledge to uphold scientific standards and testing rigor.

Yet, while more than 40 experimental COVID-19 vaccines are being tested on humans, the insurance companies with decades of experience in assessing the risks of clinical trials don’t see anything to be unduly concerned about.

Executives at insurer Allianz and brokers Gallagher and Marsh, among the leading players in clinical trials insurance, told Reuters that premiums had only marginally increased so far in the current pandemic.

They argued there was little structural difference to trials carried out in the past, despite drugmakers around the world competing to shatter the fastest time in history for developing a vaccine, which stands at around four years.

“Rates have been relatively stable. Even this year we have so far seen only moderate price increases on average, with higher price jumps for particularly exposed COVID-19 trials,” said Mark Piazzi, senior underwriter liability at Allianz Global Corporate & Specialty.

This was echoed by David Briggs, managing director, life sciences practice at Gallagher, who said every trial was rated on its methods and the kinds of patients involved.

Gallagher said premiums in Britain, for example, started at about 5,000 pounds ($6,500) per trial.

Total claims limits in policies were typically set at roughly $6-12 million, depending on the country’s rules, according to several insurance companies interviewed by Reuters.

In Britain, for instance, claim limits were usually set at no lower than 5 million pounds, while in Germany the figure was around 10 million euros ($11.8 million).

‘LOSS EXPERIENCE NOT DRAMATIC’

However part of the reason why premiums have not risen as sharply as some people might have expected is that claims from trial are generally uncommon, according to executives. This is because patients have often signed so-called informed consent agreements, they said.

Jim Walters, managing director of Life Sciences & Chemical Group at broker Aon, said such agreements outlined the risks that patients were taking by participating in the trial.

“So, you know, everything from you could have a sore spot on your arm. To you could potentially die. And you know, they would literally go that far in some of these protocols,” he added.

“Those generally tend to hold up in courts and in legal systems around the world. That means that the loss experience coming out of clinical trials is not very dramatic.”

Claims are often limited to circumstances linked to the improper conduct of trials or any wrongdoing, rather than side-effects of the treatment, executives said.

Such have been the worries about the vaccine race among some members of the public, who fear safety standards could slip, that nine developers issued a joint pledge last month to “uphold the integrity of the scientific process”.

ASTRAZENECA TRIAL SUSPENSION

AstraZeneca and Oxford University’s suspension of global Phase III trials of their experimental COVID-19 vaccine early last month due to a participant’s illness brought the risk of side effects in clinical trials to the public fore.

But the insurers said such delays were not unexpected, and could even reflect the extra caution of vaccine developers given the lack of data about COVID-19.

“Side effects always happen with clinical trials, but these are typically mild and expected. It is not very common to delay or suspend trials, it does happen though,” said Piazzi at AGCS, whose main peers in underwriting trials include Chubb, HDI and Fairfax’s Newline.

“Pharma companies and insurers alike are even more careful than usual with COVID-19 trials because there is so much at stake, particularly for the patients’ safety.”

All trials of the vaccine candidate have resumed, with the exception of the U.S. study.

There have been examples in recent memory of drug trials going catastrophically wrong, though.

In 2016, for instance, one participant died and five were hospitalized in a Phase I trial run by French company Biotrial in the city of Rennes, testing an experimental mood brightener made by Portuguese drugmaker Bial.

In 2006, six patients required intensive care after receiving a potential treatment against leukemia and auto-immune disease in London. One was described as looking like “the elephant man” after his head swelled. Another lost fingertips and toes. Germany’s TeGenero, the initial developer of the medicine, folded.

But insurance executives stress such disasters are rare, given the thousands of clinical drug trials being carried out every year.

Walters of Aon, speaking about the 2016 trial, said it was “obviously a horrible situation”.

“But that’s one of very few incidents of really bad loss experience that the industry has faced. So, clinical trial insurance is not hugely expensive. Let’s put it that way.”

(Reporting by Noor Zainab Hussain, Carolyn Cohn and Ludwig Burger; Editing by Pravin Char)

Caterpillar bets on self-driving machines impervious to pandemics

By Rajesh Kumar Singh

CHICAGO (Reuters) – Question: How can a company like Caterpillar try to counter a slump in sales of bulldozers and trucks during a pandemic that has made every human a potential disease vector?

Answer: Cut out human operators, perhaps?

Caterpillar’s autonomous driving technology, which can be bolted on to existing machines, is helping the U.S. heavy equipment maker mitigate the heavy impact of the coronavirus crisis on sales of its traditional workhorses.

With both small and large customers looking to protect their operations from future disruptions, demand has surged for machines that don’t require human operators on board.

Sales of Caterpillar’s autonomous technology for mining operations have been growing at a double-digit percentage clip this year compared with 2019, according to previously unreported internal company data shared with Reuters.

By contrast, sales of its yellow bulldozers, mining trucks and other equipment have been falling for the past nine months, a trend that’s also hit its main rivals including Japan’s Komatsu Ltd and American player Deere & Co.

Fred Rio, worldwide product manager at Caterpillar’s construction digital & technology division, told Reuters that a remote-control technology, which allows users to operate machines from several miles away, would be available for construction sites in January.

The company is also working with space agencies to use satellite technology to allow an operator sitting in the United States to remotely communicate with machines on job sites in, say, Africa or elsewhere in the world, he said.

Caterpillar’s automation strategy was not born during the COVID-19 era, though. The company stepped up investments in such technologies as it emerged in 2017 from the longest downturn in its history, as part of a plan to increase recurring revenue from lucrative sales of services.

But it’s early days, and such tech remains a niche part of Caterpillar’s operations. Though it does not break out the revenue from technology sales, the rising demand is unlikely to make a major impact anytime soon on the group’s revenue, which stood at about $54 billion last year.

It is also a costly endeavor with the company pumping billions into R&D as a whole. Yet it is not clear if demand for autonomous and remote tech will hold up in a post-pandemic world while, in the longer term, there is the risk that a technology-driven improvement in productivity could drive down sales of new equipment.

‘IT HAS GOT CRAZIER’

Nonetheless, autonomous technology is helping Caterpillar win equipment deals from customers that were previously not buying a lot of its machines.

Last year, Rio Tinto signed up the company to supply self-driving trucks, autonomous blast drills, loaders and other machines for the construction of the Koodaideri iron ore mine in Australia, which is expected to be operational next year.

Rio Tinto declined to comment on the equipment deal.

The mining industry has already adopted some technologies for self-driving trucks and remote operation of load-haul-dump machines. However the suspension in activities worldwide following government-mandated lockdowns at the peak of COVID-19, as well as recent outbreaks of infections at coal mines in Poland, have accelerated the deployment of those technologies.

Anthony Cook, general manager for autonomous haulage systems at Caterpillar’s rival Komatsu, said a lot of customers had brought forward their spending plans following the pandemic in a bid to take drivers out of mining trucks.

He said the COVID-19 crisis had not hit the fortunes of his autonomous business: “If anything, it has got crazier.”

CATERPILLAR’S IN SPACE

Caterpillar and Komatsu hold the lion’s share of the global autonomous haulage system market worldwide.

But Illinois-based Caterpillar has a competitive advantage, according to some analysts, as its technology can be retrofitted onto competitors’ equipment, making it a better fit for mixed fleets. Komatsu’s technology currently only works with its own machines.

Komatsu’s Cook said that while retrofitting offered a short-term solution, his company was developing technology to allow different brands of equipment to operate together “safely and efficiently”, which he added would offer long-term benefits.

But Jim Hawkins, general manager at Caterpillar’s resource industries division, said the ability to retrofit had helped drive up sales, because mining companies can buy the hardware and software to make machines operate autonomously without paying the much larger cost of overhauling their whole fleet.

That is a selling point at a time when miners are grappling with the virus-induced business uncertainty.

Caterpillar sells autonomous operation technology separately from its machines. While retrofitting existing fleets has been the biggest driver for growth until now, Hawkins says an increasing number of customers are now ordering autonomous-ready mining trucks.

The company charges mining customers a hardware fee, a software fee and recurring licensing fee. In all, the technology could cost from $50 million to hundreds of millions of dollars, depending upon the size of the fleet and the duration of the contract, Hawkins said.

All these applications are part of the company’s endeavor to increases services revenue, which tends to be more resilient and profitable than equipment sales. It aims to increase services sales to $28 billion by 2026 from $18 billion in 2019.

Rob Wertheimer, machinery analyst at Melius Research, said the need for mining companies to replace an aging mining fleet and their growing demand for autonomous upgrades should help Caterpillar, with its tech giving it a “differential” advantage over rivals.

“Strategically, they are in a better place,” he added.

(Reporting by Rajesh Kumar Singh; Editing by Joe White and Pravin Char)